nav-left cat-right
cat-right

NIH publishes first Alzheimer’s genomics dat...

The National Institutes of Health said Monday it has made available for researchers the first batch of genome sequence data from the Alzheimer’s Disease Sequencing Project (ADSP). Established in February 2012 by a Presidential Initiative, the ADSP is a national research project with the aim of finding ways to prevent or effectively treat the memory-stealing disease. Using large-scale genome sequencing, the National...

Merck Serono, Kadimastem collaborate on cell-based...

Kadimastem has developed technologies to differentiate stem cells into oligodendrocytes, which are brain cells that produce myelin, the insulation for the neural wiring. In multiple sclerosis (MS), oligodendrocytes are destroyed by the immune system. Kadimastem and Merck Serono have been leveraging cell-based drug screening technology to discover compounds that stimulate differentiation and myelination. Such compounds may...

J&J innovation team sets up international col...

Johnson & Johnson ($JNJ) has spent hundreds of millions of dollars in a so-far failed effort to develop a late-stage biologic that could be used to treat Alzheimer’s. And it’s now prepared to spend hundreds of millions more as it goes back to the drawing board to explore the molecular underpinnings of the disease in an attempt to find new therapies that promise to thwart the disease before it cripples the...

Molecule could treat a wide range of CNS disorders

Scientists at the Cambridge, MA, startup Sage Therapeutics have discovered an innate mechanism that indirectly influences a key receptor linked to a number of neurologic and psychiatric disorders, including Alzheimer’s, schizophrenia, autism and depression. The newly discovered natural allosteric modulator influences the N-methyl-D-aspartate (NMDA) receptor, which is known to play a role in regulating synaptic function...

Compound restores learning, memory loss in mice

Australian Prana Biotechnology has published new data showing that its metal-transporting compound PBT2 reversed memory and learning loss associated with the aging process in elderly mice. The study, published in the journal Aging Cell, is the latest to support the drug’s use for the treatment of Alzheimer’s disease. “It is very exciting to discover that PBT2 not only helps clear amyloid from the brain, but...

Alzheimer’s team tackles a daunting R&D...

Martin Tolar is an old hand when it comes to striking deals for experimental Alzheimer’s drugs. As CEO at CoMentis, he reaped a $100 million cash windfall from a 2008 licensing pact with Astellas on a beta secretase inhibitor. And before that, he worked deals for Pfizer ($PFE). Today, after wrapping a short stint as CEO of Knome, the veteran biotech player is back in the Alzheimer’s drug game, launching a new...
Page 4 of 8« First...23456...Last »